Arcutis Biotherapeutics Hits New 52-Week High of $20.10, Up 162%

Arcutis Biotherapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 20.10 on October 1, 2025. This achievement underscores the company's remarkable performance over the past year, with a staggering 162.07% increase compared to the S&P 500's 16.09% gain during the same period. The company has demonstrated strong growth, particularly in net sales, which surged by 164.13%. Arcutis has reported positive results for seven consecutive quarters, reflecting its operational resilience. Despite being a loss-making entity, the company has shown improvements in key financial metrics, including a notable reduction in raw material costs by 2.32% year-over-year. With a market capitalization of USD 2,080 million, Arcutis Biotherapeutics is positioned strongly within its industry. The stock's performance has been bolstered by high institutional holdings, indicating a robust confidence in its fundamentals. As it continues to navigate the competitive landscape, the recent price milestone highlights the company's ongoing growth trajectory.